Relugolix and degarelix are both effective in achieving and maintaining sustained castration in advanced prostate cancer. Relugolix’s oral form provides convenience, eliminating the need for frequent ...

A targeted cancer drug niraparib, used in combination with hormone therapy, was found to reduce the risk of prostate tumor growth and slow symptom advance. File Photo by Billie Jean Shaw/UPI A new ...

A drug for advanced prostate cancer has shown “remarkable” results in an early-stage trial, with patients who had previously stopped being receptive to treatment finding their tumours shrinking, ...

Advanced prostate cancer treatment requires a personalized approach, considering disease stage, comorbidities, and patient preferences. ARPIs have revolutionized treatment, highlighting the need for ...

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...

If you’re dealing with advanced prostate cancer, the thought of surgery might feel like a lot to take in — and that’s completely understandable. For many men facing an advanced diagnosis, surgery will ...

Experts project the diagnosis of over 300,000 prostate cancer cases in the United States in 2006, along with over 30,000 prostate cancer-related deaths. As such, prostate cancer remains the most ...

The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with high-risk ...

*Localized: T 1/2, NX or N0, and M0. ‡ Locally advanced: T3/4, NX or N0, and M0, or N1 and M0. ITT: Intention to treat; PSA: Prostate-specific antigen. Reproduced ...

PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) said it has received “study may proceed” clearance from the U.S. Food ...

(BPT) – This content is sponsored and provided by Myovant Sciences and Pfizer Inc. After retiring, Mike settled into Arlington, Virginia, right outside of Washington, D.C., where he was a teacher for ...